No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.
The FTSE 100-listed group noted that Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease.
GSK said a European regulatory decision was expected to be reached during H126 and stated it was continuing to seek expanded indications for its RSV vaccine in other countries, including the US and Japan.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.